24 results on '"Christen, Thomas"'
Search Results
2. Intracardiac Echocardiography to Guide Watchman FLX Implantation: The ICE LAA Study
3. Streamlined magnetic resonance fingerprinting: Fast whole-brain coverage with deep-learning based parameter estimation
4. Using digital health technology to evaluate the impact of chocolate on blood pressure: Results from the COCOA-BP study
5. One-Year Outcomes in “Real-World” Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent (from the PROMUS Element Plus US Post-Approval Study [PE-Plus PAS])
6. Contrast-enhanced functional blood volume imaging (CE-fBVI): Enhanced sensitivity for brain activation in humans using the ultrasmall superparamagnetic iron oxide agent ferumoxytol
7. Hypoxia But Not Inflammation Augments Glucose Uptake in Human Macrophages: Implications for Imaging Atherosclerosis With 18Fluorine-Labeled 2-Deoxy-D-Glucose Positron Emission Tomography
8. TCT-33 Racial Disparities in the Utilization and Outcomes of LAA Occlusion Using Watchman FLX: A SURPASS analysis of the NCDR LAAO Registry
9. PO-03-134 LONG TERM OUTCOMES FOLLOWING LAAO IN A LARGE MEDICARE POPULATION
10. CE-452771-4 OUTCOMES WITH DIFFERENT POSTPROCEDURAL ANTITHROMBOTIC THERAPY REGIMENS FOLLOWING LEFT ATRIAL APPENDAGE OCCLUSION
11. CE-452771-3 LEFT ATRIAL APPENDAGE OCCLUSION WITH THE WATCHMAN FLX AND CONCOMITANT CATHETER ABLATION PROCEDURES
12. PO-656-04 SAFETY AND EFFECTIVENESS OF SAME DAY DISCHARGE AFTER LEFT ATRIAL APPENDAGE OCCLUSION WITH WATCHMAN FLX
13. B-PO01-078 REAL-WORLD CLINICAL OUTCOMES WITH A NEXT-GENERATION LEFT ATRIAL APPENDAGE CLOSURE DEVICE: FIRST REPORT FROM THE FLXIBILITY POST-APPROVAL STUDY
14. B-PO01-044 REAL WORLD OUTCOMES WITH WATCHMAN: 2-YEAR RESULTS FROM THE NESTED POST APPROVAL STUDY
15. A FIRST-IN-HUMAN STUDY OF THE SECOND-GENERATION, THIN-STRUT, EVEROLIMUS-ELUTING BIORESORBABLE SCAFFOLD: 6-MONTH IVUS AND OCT RESULTS FROM THE FAST CLINICAL TRIAL
16. TCT-583 Final 5-Year Results in Unselected Patients Implanted With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent: The PROMUS Element Plus US Post-Approval Study
17. CLINICAL OUTCOMES TO 4 YEARS IN PATIENTS IMPLANTED WITH BIOABSORBABLE POLYMER SYNERGY VERSUS PERMANENT POLYMER EVEROLIMUS-ELUTING STENTS: THE EVOLVE II RANDOMIZED TRIAL
18. TCT-846 Clinical Outcomes in Patients Treated With the Fully Absorbable, Everolimus-Eluting RENUVIATM Scaffold: Primary Endpoint Results from the FAST First Human Use Study
19. TCT-729 Four-Year Clinical Outcomes in ‘Real-World’ Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent: Results from the PROMUS Element Plus US Post-Approval Study (PE-Plus PAS)
20. THREE-YEAR OUTCOMES IN ‘REAL-WORLD’ PATIENTS TREATED WITH A THIN-STRUT, PLATINUM-CHROMIUM, EVEROLIMUS-ELUTING STENT IN THE PROMUS ELEMENT PLUS U.S. POST-APPROVAL STUDY (PE-PLUS PAS)
21. THREE-YEAR RESULTS FROM THE EVOLVE II RANDOMIZED TRIAL: LATE CLINICAL OUTCOMES WITH BIORESORBABLE COMPARED TO PERMANENT POLYMER EVEROLIMUS-ELUTING
22. TCT-167 Primary Endpoint Results of the TAXUS Libertē Post-Approval Study
23. TCT-148 TAXUS Liberté paclitaxel-eluting stent with aspirin plus prasugrel is associated with low target vessel failure, bleeding and adverse event rates among diabetic patients with "on-label" stent indications
24. THE DELETION OF CONNEXIN37 ENHANCES ATHEROSCLEROSIS IN APOLIPOPROTEIN E-DEFICIENT MICE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.